CME Group (NASDAQ:CME) Price Target Raised to $287.00

Key Points

• CME Group's target price was raised from $283.00 to $287.00 by Keefe, Bruyette & Woods, indicating a potential upside of 5.73%.
• Despite varying evaluations from analysts, the consensus price target for CME Group is $283.43, with seven analysts rating it a Buy and two a Sell.
• The company reported an earnings per share (EPS) of $2.96 for the last quarter, surpassing expectations and showing a year-over-year revenue increase of 10.4%.

CME Group (NASDAQ:CME - Get Free Report) had its target price boosted by stock analysts at Keefe, Bruyette & Woods from $283.00 to $287.00 in a research report issued on Monday,MarketScreener reports. The brokerage currently has a "market perform" rating on the financial services provider's stock. Keefe, Bruyette & Woods' target price indicates a potential upside of 5.73% from the stock's current price.

Several other equities research analysts have also weighed in on the company. UBS Group reduced their price objective on shares of CME Group from $305.00 to $285.00 and set a "neutral" rating for the company in a research note on Monday, September 8th. Morgan Stanley upped their price target on shares of CME Group from $303.00 to $312.00 and gave the company an "overweight" rating in a research report on Wednesday, October 1st. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of CME Group from $276.00 to $266.00 and set a "hold" rating for the company in a research note on Thursday. Barclays cut their target price on shares of CME Group from $298.00 to $280.00 and set an "equal weight" rating on the stock in a research note on Wednesday. Finally, Raymond James Financial restated an "outperform" rating and set a $307.00 price target on shares of CME Group in a report on Monday. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $283.43.

CME Group Stock Up 1.0%

CME opened at $271.45 on Monday. The stock has a market cap of $97.83 billion, a P/E ratio of 26.28, a P/E/G ratio of 5.72 and a beta of 0.41. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.02 and a quick ratio of 1.02. CME Group has a 12 month low of $213.94 and a 12 month high of $290.79. The stock's 50 day moving average price is $268.89 and its 200 day moving average price is $271.29.

CME Group (NASDAQ:CME - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The financial services provider reported $2.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.91 by $0.05. CME Group had a return on equity of 14.60% and a net margin of 58.48%.The company had revenue of $1.69 billion for the quarter, compared to analysts' expectations of $1.68 billion. During the same period last year, the firm earned $2.56 EPS. The firm's revenue for the quarter was up 10.4% on a year-over-year basis. As a group, research analysts predict that CME Group will post 10.49 earnings per share for the current year.

Insider Buying and Selling at CME Group

In other news, Director William R. Shepard purchased 262 shares of CME Group stock in a transaction dated Thursday, September 25th. The shares were bought at an average cost of $265.19 per share, with a total value of $69,479.78. Following the completion of the transaction, the director directly owned 258,459 shares in the company, valued at $68,540,742.21. This trade represents a 0.10% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Timothy Francis Mccourt sold 379 shares of the business's stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $259.83, for a total transaction of $98,475.57. Following the completion of the transaction, the insider directly owned 9,508 shares of the company's stock, valued at $2,470,463.64. This trade represents a 3.83% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,043 shares of company stock worth $3,527,956. 0.30% of the stock is currently owned by insiders.

Institutional Trading of CME Group

Several hedge funds have recently bought and sold shares of the stock. Heartland Bank & Trust Co acquired a new position in shares of CME Group during the first quarter worth about $377,000. Catalyst Capital Advisors LLC lifted its stake in CME Group by 256.9% in the 1st quarter. Catalyst Capital Advisors LLC now owns 3,662 shares of the financial services provider's stock valued at $971,000 after acquiring an additional 2,636 shares in the last quarter. OMNI 360 Wealth Inc. acquired a new position in CME Group during the 1st quarter worth approximately $367,000. Fulcrum Equity Management acquired a new position in CME Group during the 1st quarter worth approximately $258,000. Finally, AIA Group Ltd grew its stake in shares of CME Group by 17.8% during the 1st quarter. AIA Group Ltd now owns 16,645 shares of the financial services provider's stock worth $4,416,000 after acquiring an additional 2,510 shares in the last quarter. 87.75% of the stock is currently owned by institutional investors and hedge funds.

CME Group Company Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.